rAAV1.CMV.huFollistatin344

Phase 1Gene therapy

rAAV1.CMV.huFollistatin344 is one of 7 biologic programs targeting Becker muscular dystrophy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Becker Muscular DystrophyActive, not recruiting

Becker Muscular DystrophyPhase 1

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Becker Muscular Dystrophy

#DrugCompanyPhaseTrials

Translarna

PPTC Therapeutics

Phase 2

4 2

Viagra

VViatris Specialty LLC

Phase 2

1 3

Duvyzat

Italfarmaco

Phase 2

1 4

Cialis

Eli Lilly

Phase 1

2 5

Agamree

CCatalyst Biosciences

Phase 2

1 6

Sevasemten

EEdgewise Therapeutics, Inc.

Phase 2

3 7

rAAV1.CMV.huFollistatin344

NNationwide Children's Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Becker muscular dystrophy1 trial

Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis

Completed·NNationwide Children's Hospital·Phase 1·NCT01519349·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for rAAV1.CMV.huFollistatin344. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rAAV1.CMV.huFollistatin344 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rAAV1.CMV.huFollistatin344. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nationwide Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 1[1]
Company: NNationwide Children's Hospital

rAAV1.CMV.huFollistatin344

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Becker muscular dystrophy1 trial

References

Drug Info

Quick Facts

Related News